Abstract
Purpose
Current strategies for avoiding atrial fibrillation (AF) are of limited value. We aim to assess the relationship between omega-3 fatty acids (n-3 PUFA) and AF occurrence in post-myocardial infarction (MI) patients.
Methods
A population study, linking hospital discharge records, prescription databases, and vital statistics, was conducted and included all consecutive patients with MI (ICD-9: 410) in six Italian local health authorities over a 3-year period. A propensity score (PS)-based, 5-to-1, greedy 1:1 matching algorithm was used to check consistency of results. Sensitivity analysis was performed to assess the robustness of findings.
Results
N-3 PUFA reduced the relative risk of the hospitalization for AF [hazard ratio (HR) 0.19, 95% CI 0.07–0.51] and was associated with a further and complementary reduction in all-cause mortality (HR 0.15, 95% CI 0.05–0.46). PS-based matched analysis and sensitivity analysis confirmed the main results.
Conclusion
n-3 PUFA reduced both all-cause mortality and incidence of 1-year AF in patients hospitalized with MI.
Similar content being viewed by others
References
Bialy D, Lehmann MH, Schumacher DN et al (1992) Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol 19:41A (abstract)
Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988
Furberg CD, Psaty BM, Manolio TA et al (1994) Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74:236–241
Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375
Majeed A, Moser K, Carroll K (2001) Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 86:284–288
Ezekowitz MD (1999) Atrial fibrillation: the epidemic of the new millennium. Ann Intern Med 131:537–538
Ryder KM, Benjamin EJ (1998) Epidemiology and significance of atrial fibrillation. Am J Cardiol 84:131R–138R
Sudlow M, Thomson R, Thwaites B et al (1998) Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 352:1167–1171
Butler RN (1997) Population aging and health. BMJ 315:1082–1084
MacIntyre K, Capewell S, Stewart S et al (2000) Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 102:1126–1131
Capewell S, MacIntyre K, Stewart S et al (2001) Age, sex and social trends in out-of-hospital cardiac deaths in Scotland 1986–1995: a retrospective cohort study. Lancet 358:1213–1217
Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356:1789–1794
Wyse DG, Waldo AL, DiMarco JP et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833
Carlsson J, Miketic S, Windeler J et al; STAF investigators (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41:1690–1696
Van Gelder IC, Hagens VE, Bosker HA et al (2002) Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840
Opolski G, Torbicki A, Kosior DA et al; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 126:476–486
de Denus S, Sanoski CA, Carlsson J et al (2005) Rate vs rhythm control in patients with atrial fibrillation a meta-analysis. Arch Intern Med 165:258–262
Camm JA, Savelieva I (2004) Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm 1:244–246
Kromhout D, Feskens EJ, Bowles CH (1995) The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 24:340–345
Daviglus ML, Stamler J, Orencia AJ et al (1997) Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336:1046–1053
Yuan JM, Ross RK, Gao YT et al (2001) Fish and shellfish consumption in relation to death from myocardial infarction among men in Shanghai, China. Am J Epidemiol 154:809–816
Hu FB, Bronner L, Willett WC et al (2002) Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287:1815–1821
Mozaffarian D, Lemaitre RN, Kuller LH et al (2003) Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 107:1372–1377
Fraser GE, Sabate J, Beeson WL et al (1992) A possible protective effect of nut consumption on risk of coronary heart disease: the Adventist Health Study. Arch Intern Med 152:1416–1424
Rodriguez BL, Sharp DS, Abbott RD et al (1996) Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: the Honolulu Heart Program. Circulation 94:952–956
Albert CM, Hennekens CH, O’Donnell CJ et al (1998) Fish consumption and risk of sudden cardiac death. JAMA 279:23–28
Burr ML, Fehily AM, Gilbert JF et al (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 30:757–761
GISSI Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354:447–455
Marchioli R, Barzi F, Bomba E et al; GISSI-Prevenzione Investigators (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897–1903
Mozaffarian D, Psaty BM, Rimm EB et al (2004) Fish intake and risk of incident atrial fibrillation. Circulation 110:368–373
Frost L, Vestergaard P (2005) n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 81:50–54
Brouwer IA, Heeringa J, Geleijnse JM et al (2006) Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation: the Rotterdam Study. Am Heart J 151:857–862
Calo L, Bianconi L, Colivicchi F et al (2005) N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45:1723–1728
Marchioli R, Marfisi RM, Borrelli G et al (2007) Efficacy of n-3 polyunsatured fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovas Med 8(Suppl 1):S34–S37
OsMed (Osservatorio Nazionale sull’Impiego dei Medicinali) (2005) L’uso dei Farmaci in Italia-Rapporto Nazionale anno 2004. Il Pensiero Scientifico Editore, Roma. http://www.ministerosalute.it/medicinali/osmed/osmed.jsp
Monte S, Macchia A, Pellegrini F et al (2006) Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27:2217–2223
Macchia A, Monte S, Romero M et al (2007) The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Failure 9:942–948
D’Ettorre A (2005) ReClust: technical report. http://easi.negrisud.it/software/reclust/index.html
US Dept of Health and Human Services (1998) International classification of diseases, 9th revision (clinical modification). Public Health Service, US Department of Health and Human Services, Washington DC
WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC index with DDDs. WHO, Oslo
D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
Yanovitzky I, Zanutto E, Hornik R (2005) Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 28:209–220
Parsons LS (2004) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. SAS Institute, Cary, NC
Lin DY, Psaty BM, Krommal RA (1998) Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948–963
Crenshaw BS, Ward SR, Granger CB et al (1997) Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global utilization of streptokinase and TPA for occluded coronary arteries. J Am Coll Cardiol 30:406–413
Eldar M, Canetti M, Rotstein Z et al (1998) Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 97:965–970
Pizzetti F, Turazza FM, Franzosi MG et al; GISSI-3 Investigators (2001) Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86:527–532
Pedersen OD, Bagger H, Kober L et al (1999) The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 20:748–754
Folkeringa RJ, Tieleman RG, Crijns HJ (2004) Non-antiarrhythmic drugs to prevent atrial fibrillation. Heart Rhythm 1:516–518
Vermes E, Tardif JC, Bourassa MG et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931
Maggioni AP, Latini R, Carson PE et al; Val-HeFT Investigators (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548–557
Disertori M, Latini R, Maggioni AP et al; GISSI-AF Investigators (2006) Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 7:29–38
Jordan H, Matthan N, Chung M et al (2004) Effects of omega-3 fatty acids on arrhythmogenic mechanisms in animal and isolated organ/cell culture studies. Evid Rep Technol Assess 92:1–8
Jahangiri A, Leifert WR, Patten GS et al (2000) Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids. Mol Cell Biochem 206:33–41
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Macchia, A., Monte, S., Pellegrini, F. et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 64, 627–634 (2008). https://doi.org/10.1007/s00228-008-0464-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0464-z